全文获取类型
收费全文 | 164篇 |
免费 | 8篇 |
国内免费 | 3篇 |
专业分类
基础医学 | 27篇 |
临床医学 | 18篇 |
皮肤病学 | 5篇 |
神经病学 | 2篇 |
特种医学 | 1篇 |
外科学 | 29篇 |
综合类 | 41篇 |
预防医学 | 12篇 |
药学 | 7篇 |
1篇 | |
中国医学 | 30篇 |
肿瘤学 | 2篇 |
出版年
2024年 | 4篇 |
2023年 | 5篇 |
2022年 | 6篇 |
2021年 | 3篇 |
2020年 | 2篇 |
2019年 | 9篇 |
2018年 | 8篇 |
2017年 | 8篇 |
2016年 | 6篇 |
2014年 | 15篇 |
2013年 | 11篇 |
2012年 | 8篇 |
2011年 | 15篇 |
2010年 | 6篇 |
2009年 | 6篇 |
2008年 | 9篇 |
2007年 | 7篇 |
2006年 | 10篇 |
2005年 | 3篇 |
2004年 | 3篇 |
2003年 | 6篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1998年 | 2篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1989年 | 1篇 |
排序方式: 共有175条查询结果,搜索用时 15 毫秒
31.
目的研究人脑神经胶质瘤组织中CtBP1蛋白的表达,旨在了解其与人脑神经胶质瘤恶性生物学行为之间的关系,并探讨其在人脑胶质瘤中的作用及其临床意义。方法采用免疫组织化学测定50例人脑神经胶质瘤手术切除标本及6例癫痫患者手术切除的正常脑组织标本中CtBP1的表达水平变化。结果 CtBP1蛋白的表达随着人脑胶质瘤级别的升高而逐渐升高,而在正常脑组织中表达水平极低;正常脑组织组、低级别人脑胶质瘤组及高级别组之间表达的差异有明显统计学意义(P<0.05);CtBP1蛋白的表达水平与人脑胶质瘤的病理级别之间呈现正相关(P<0.05)。结论 CtBP1蛋白的高表达可以反映人神经脑胶质瘤的恶性生物学行为,在人脑胶质瘤的发生过程中起着重要作用,它可能是脑胶质瘤抗凋亡、恶性增殖的一个关键性的调控因子。 相似文献
32.
目的:探讨逆行腔内注射超声造影剂辅助超声引导下经皮肾穿刺技术处理无积水肾合并肾结石的可行性及安全性。方法:选取鄂东医疗集团市中心医院2014年1月至2016年8月行逆行输尿管注射超声造影剂辅助超声引导下经皮肾镜取石术(PCNL)的60例肾结石患者。右肾结石患者25例;左肾结石患者35例。肾结石位于肾盂或者肾盏。术中通过... 相似文献
33.
目的:探讨分析老年肾癌患者血清T淋巴细胞亚群变化对其预后及生存的影响。方法:选择2013年4月至2015年3月我院收治的78例老年肾癌患者,再选择同期来我院体检的健康人群50例作为对照组,术前以及术后2周采用流式细胞技术检测肾癌患者外周血T淋巴细胞亚群水平变化情况,并与对照组比较。对患者进行随访分析,采用Kaplan-Meier生存分析术后不同T淋巴细胞亚群水平对患者生存预后的影响。结果:肾癌组患者术前、术后2周外周血CD3+、CD4+以及CD4+/CD8+水平均显著低于对照组(P<0.05)。肾癌组术后2周外周血CD3+、CD4+以及CD4+/CD8+水平较术前有显著升高(P<0.05)。CD3+>48%肾癌患者总体生存情况显著优于CD3+≤48%患者(P<0.05)。CD4+>30%肾癌患者总体生存情况显著优于CD4+≤30%患者(P<0.05)。CD8+>25%肾癌患者总体生存情况与CD8+≤25%患者生存情况无差异(P>0.05)。CD4+/CD8+>1.0肾癌患者总体生存情况显著优于CD4+/CD8+≤1.0患者(P<0.05)。结论:老年肾癌患者存在广泛的细胞免疫功能紊乱现象,手术治疗后能够有效去除瘤负荷而从一定程度上逆转免疫功能,术后免疫功能指标可反映患者预后情况,免疫功能状态越差的患生存情况越差。 相似文献
34.
<正> 由于椎动脉受压致脑部供血不足而发生的眩晕称为颈性眩晕。笔者采用手法治疗因环枢椎发生错位所致的颈性眩晕16例,收到较好效果,现报告如下。一、临床资料16例中,男12例,女4例;年龄最小28岁,最大57岁,平均36.7岁;干部5例,工人10例,农民1例;病程最短12天,最长4年,平均1年零9个月。16例中眩晕、颈痛、头颈转动不利者16例,耳鸣者7例,恶心者2例,手指麻木者5例,失眠者1例。X 线颈椎正、侧位片:两侧环齿间隙不等宽 相似文献
35.
目的:探讨对于留置永久性心脏起搏器的前列腺增生患者的经尿道前列腺电切(TURP)治疗方法.方法:回顾我院1997年1月~2007年6月7例留置永久性心脏起搏器前列腺增生患者的TURP治疗.患者年龄62~75岁,留置永久性心脏起搏器1~5年,其中病态窦房结综合征4例、Ⅲ度房室传导阻滞2例、三束支传导阻滞1例,起搏器类型为房室全能型(DDD)3例、心房按需型(AAI)2例、心室按需型(VVI)2例.结果:患者手术过程顺利,术中生命体征平稳,术后恢复良好.结论:留置心脏起搏器并非TURP的绝对禁忌证,此类患者经过充分准备可以承受手术治疗. 相似文献
36.
37.
Objective To investigate the effect of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) as adjuvant on immune response in adults of non-and hyporesponders to hepatitis B vaccine. Methods Those who were once immunized with recombined yeast gene hepatitis B vaccine more than one standard scheme in two years and negative for hepatitis B markers were randomly sorted as group A and group B. 33 adults of group A were given hepatitis B vaccine 10 μg each time. The immune procedure was O, 1 and 6month. 34 adults of group B were given rhGM-CSF 300 μg for the first day, then 10 μg each time for routine immune. The blood samples were collected before the first injection and in 1, 2 and 8 months (T1, T2, TS)following the first injection to test Anti-HBs. Results Anti-HBs positive conversion rates of group A and B at T8 was 39.39% and 64.71% respectively(P=0.038). Anti-HBs levels of group B at TI, T2, T8 were(113.85±198.56) mIU/ml, (312.40±349.44) mIU/ml, (427.74±411. 58) mIU/ml (P=0.001). There was significant difference between group A and B in T8 Anti-HBs levels(P=0.010). Conclusion Better immune response was found in the group of rhGM-CSF with hepatitis B vaccine. So rhGM-CSF can induce the immune respond to hepatitis B vaccine. 相似文献
38.
Objective To investigate the effect of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) as adjuvant on immune response in adults of non-and hyporesponders to hepatitis B vaccine. Methods Those who were once immunized with recombined yeast gene hepatitis B vaccine more than one standard scheme in two years and negative for hepatitis B markers were randomly sorted as group A and group B. 33 adults of group A were given hepatitis B vaccine 10 μg each time. The immune procedure was O, 1 and 6month. 34 adults of group B were given rhGM-CSF 300 μg for the first day, then 10 μg each time for routine immune. The blood samples were collected before the first injection and in 1, 2 and 8 months (T1, T2, TS)following the first injection to test Anti-HBs. Results Anti-HBs positive conversion rates of group A and B at T8 was 39.39% and 64.71% respectively(P=0.038). Anti-HBs levels of group B at TI, T2, T8 were(113.85±198.56) mIU/ml, (312.40±349.44) mIU/ml, (427.74±411. 58) mIU/ml (P=0.001). There was significant difference between group A and B in T8 Anti-HBs levels(P=0.010). Conclusion Better immune response was found in the group of rhGM-CSF with hepatitis B vaccine. So rhGM-CSF can induce the immune respond to hepatitis B vaccine. 相似文献
39.
Objective To investigate the effect of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) as adjuvant on immune response in adults of non-and hyporesponders to hepatitis B vaccine. Methods Those who were once immunized with recombined yeast gene hepatitis B vaccine more than one standard scheme in two years and negative for hepatitis B markers were randomly sorted as group A and group B. 33 adults of group A were given hepatitis B vaccine 10 μg each time. The immune procedure was O, 1 and 6month. 34 adults of group B were given rhGM-CSF 300 μg for the first day, then 10 μg each time for routine immune. The blood samples were collected before the first injection and in 1, 2 and 8 months (T1, T2, TS)following the first injection to test Anti-HBs. Results Anti-HBs positive conversion rates of group A and B at T8 was 39.39% and 64.71% respectively(P=0.038). Anti-HBs levels of group B at TI, T2, T8 were(113.85±198.56) mIU/ml, (312.40±349.44) mIU/ml, (427.74±411. 58) mIU/ml (P=0.001). There was significant difference between group A and B in T8 Anti-HBs levels(P=0.010). Conclusion Better immune response was found in the group of rhGM-CSF with hepatitis B vaccine. So rhGM-CSF can induce the immune respond to hepatitis B vaccine. 相似文献
40.
Objective To investigate the effect of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) as adjuvant on immune response in adults of non-and hyporesponders to hepatitis B vaccine. Methods Those who were once immunized with recombined yeast gene hepatitis B vaccine more than one standard scheme in two years and negative for hepatitis B markers were randomly sorted as group A and group B. 33 adults of group A were given hepatitis B vaccine 10 μg each time. The immune procedure was O, 1 and 6month. 34 adults of group B were given rhGM-CSF 300 μg for the first day, then 10 μg each time for routine immune. The blood samples were collected before the first injection and in 1, 2 and 8 months (T1, T2, TS)following the first injection to test Anti-HBs. Results Anti-HBs positive conversion rates of group A and B at T8 was 39.39% and 64.71% respectively(P=0.038). Anti-HBs levels of group B at TI, T2, T8 were(113.85±198.56) mIU/ml, (312.40±349.44) mIU/ml, (427.74±411. 58) mIU/ml (P=0.001). There was significant difference between group A and B in T8 Anti-HBs levels(P=0.010). Conclusion Better immune response was found in the group of rhGM-CSF with hepatitis B vaccine. So rhGM-CSF can induce the immune respond to hepatitis B vaccine. 相似文献